We report a case of Familial hypercholesterolemia (FH) with two mutations in low density lipoprotein receptor (LDLR) gene and speculate the correlation between the newly discovered mutation type of LDLR gene and FH. We collected and analyzed the clinical data of the proband in the case and her immediate family members, and detected the LDLR, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK-9) and Apolipoprotein B (Apo B) gene in the peripheral blood of all the participants. We found that the curative effect of the patient is limited, but no obvious complication was detected. Genetic testing results pointed out that there were two mutations in the patient's LDLR gene. One was p.W483* mutation in exon 10 (c. 1448 G > A), another was p.T534I mutation in exon 11 (c. 1601 C > T). The p. W483* mutation in exon 10 was detected in the father and sister, additionally p. T534I mutation in exon 11 was detected in the mother. Both the two LDLR gene mutations are inherited from her parents. We hypothesize that the patient in this case was a complex heterozygote. The newly discovered mutation gene (T534I) may be one of the important causes of dyslipidemia in patients, and its adverse effects are more serious than W483* which have been reported. Also, we predict that the T534I mutation will not cause serious early onset of cardiovascular complications.
Introduction
Familial hypercholesterolemia (FH) is an inherited disease, which is reduced by How to cite this paper: Zhou, H., Song, X.X., Sun, B., Wu, L.J., Napawan, T. and Gu, W. (2017) Familial Hypercholesterolemia with Two Mutations in LDLR Gene: genetic defect and always characterized by abnormal metabolism of blood cholesterol [1] . Low density lipoprotein receptor (LDLR) gene mutation is the most common cause of FH. According to the severity, FH can be divided into two clinical manifestations: the relatively milder heterozygous form and more severe homozygous form [2] . It can usually be diagnosed definitely according to clinical features such as family history, blood lipid index, genetic testing and so on. At present, the therapeutic methods of FH mainly include changing lifestyle and drug treatment, in order to reduce blood lipids level and delay the progression of disease, eventually to prevent the occurrence of premature atherosclerotic cardiovascular disease. The research data among the world shows that the incidence of FH heterozygous patients is about 1/500, and about 50% of the male patients die of myocardial infarction and other cardiovascular complications before the age of 50 (female, before 60 years old) [3] [4] [5] . The morbidity of homozygous patients is 1/1,000,000 [5] . For the homozygous, the plasma low-density lipoprotein cholesterol (LDL-c) levels are higher, and body multiple xanthomas are more common. Some of the homozygous patients are more likely to an early onset and of cardiovascular diseases. Myocardial infarction (MI) even appears in some young people and even leads to death [5] . The life expectancy in the homozygous patients with standard lipid-lowering therapy is only 33 years old [6] .
FH is the main risk factor of premature atherosclerosis, coronary artery stenosis and other cardiovascular disease, therefore early recognition and intervention can reduce the morbidity and mortality of cardiovascular events effectively [7] [8].
Case Report
The patient is a 21-year-old female, whose foot and hip skin were scattered in hard and painless nodules and masses nineteen years ago. The nodules recurred rapidly and increased to the size of soybeans several months later after mass resection in local hospital. And ten years ago, both bilateral knees, elbows, finger joints of the patient presented with similar bumps. The mass at the patient's left elbow was resected seven years ago, and histopathological diagnose was shown as "xanthoma". There was little symptomatic improvement, though she went to see a doctor many times at the department of dermatology and oncology.
The first time the patient visited the Department of endocrinology of our hospital is almost three years ago. There were multiple masses on knee, elbow, and multiple interphalangeal joint (sizes from rice to soybean, moderate hardness, poor mobility) (Figure 1 ) of the patient. And the level of serum total cholesterol (TC) was 14.1 mmol/L, low density lipoprotein (LDL) was 12.47 mml/L. The patient was diagnosed with FH according to the medical history and the 2013 EAS Consensus of FH [9] . Since then, the patient has been given a therapeutic regimen with Atorvastatin and Ezetimibe Tablets successively. The serum lipid lever and hepatic function are shown in Table 1 . The sizes of the lumps on the skin are almost stable. 
Screening for Cardiovascular Complications
Electrocardiogram (ECG) was roughly normal. There were no obvious abnormality of the latest bilateral carotid and vertebral artery on ultrasound. The results of heart Doppler echocardiography indicated that the root of aortic is a thinner than normal, and the sinus tube junction is mild narrow (Figure 2 ). Coronary CTA was no obvious abnormality.
Genetic Testing
After detecting the peripheral blood of patients with LDLR, PCSK-9, Apo Bgene, two mutation sites in LDLR gene were found: p.W483* in exon 10 (c. 1448G>A);
p.T534I in exon 11 (c. 1601C > T), as shown in Figure 3 
Genealogical Analysis
We tested the LDLR gene and lipid level of the parents and elder sister. The same mutation site in exon 10 was detected in the father and sister, the same mutation was discovered in exon 11 of the mother. The blood lipid levels of them were all elevated, for details see attached Table 2 . Nobody had received treatment with drugs. Related examinations had been conducted (such as: ECG, heart Doppler ultrasound, etc.).
Discussion and Literature Review
FH is a common inherited disease, which is consistent with Mendel's law of inheritance. And FH is autosomal and dominant, towards single gene inheritance.
This disease is characterized by elevated levels of serum TC and LDL, and multiple nodular xanthomas are usually seen as the first symptoms of some patients.
Gene mutations in the gene encoding are the major causes of FH, such as LDLR, Apo B, the PCSK-9, and LDLR gene mutations are the most common [2] . 50% of the FH patients have been confirmed with one or more mutations of LDLR gene [12] , so gene detecting of LDLR is of great significance for the further research of the molecular basis of the pathogenesis of FH.
There are 1700 kinds of mutations in the LDLR gene reported on an international scale so far, domestic reports about 100 genotypes [5] . Gene mutations of
Chinese patients with FH are in exon 1 -17, and mutation of exon 18 has not been discovered, which is consistent with the worldwide mutation frequency [5] .
In addition, among all 18 exons of LDLR, exon 4 (E4) mutations cases are the frequently found mutation, which may be related to the maximum chromosome span of E4 and the selection bias the average blood TC and LDL levels of the case are significantly higher than any other family members, so we speculate that the p.T534I mutation affects LDL metabolism. detected of the proband and the mother who carries mutation p. T534I, so we speculate that the mutation will not lead to serious early onset of cardiovascular complications. And two mutations exist in LDLR gene of the propositus, the long-term prognosis of which needs the essential follow-up attention.
For suspicious individuals with a clear history of xanthoma, especially with a family history, increased serum cholesterol, and (or) a family history of premature coronary heart disease (CHD), in addition to clinical laboratory examination, genetic detecting is needed as early as possible [16] . A series of research evidence indicated that among the patients with CHD before the age of 55 patients, 5% of them accompanied with FH [4] . The risk of FH patients with CHD increased 3.5 -16 times compared to patients without FH, and serious gene mutations in homozygous patients are the decisive factors that increase the risk of cardiovascular disease (CVD) [17] . While the early recognition and treatment of individuals carrying defective genes can effectively reduce the risk of cardiovascular complications, but as a result of the complex and expensive detection technology of the LDLR molecule, the molecular detection cannot be well applied to the clinical setup.
Once the diagnoses of adult FH patients were established, lifestyle intervention should be started immediately. For patients with FH, low oil and fat is the most basic dietary requirements; in addition to appropriate physical exercise.
Drug therapy mainly includes the maximum tolerated dose of statins, ezetimibe, bile acid sequestrants, etc. For the heterozygous patients merged CHD resistant to medication and the homozygous patients, continuous veno-venous hemofiltration (CVVH) should be taken [12] . For all children with FH, low-fat diet is International Journal of Clinical Medicine unfavorable before the age of two, and drug therapy can be given after the age of eight to ten [12] . Statins are still the preferred therapy regimens for FH now. But in most cases, single drug therapy usually cannot reduce LDL to the optimal level, especially for the homozygous [2] . Recently, a clinical study on the treatment with statins of FH patients by the European Medicines Agency (EMA) has approved that most adult patients or adolescents over 12 years old with homozygous FH need the combination of statins and other lipid-lowering methods to reduce serum cholesterol [18] . Controlling the serum blood lipids is the most effective strategy to reduce the risk of cardiovascular events in patients with FH.
The research data show that only 15% of patients with FH can do regular medical visits [4] , the vast majority of patients fail to achieve the lipid control objectives, or because of side effects, stains cannot be used at a standard treatment 
Conclusion
The At the same time, more researches on the pathway of LDLR metabolism are indispensable to achieve a definite diagnosis of the LDLR deficiency types in patients with FH.
